IP Library › Granted Patent US 7,014,850
Granted Patent B2
US 7,014,850 · App. 10/067,991 · Granted Mar 21, 2006

Nasal spray for treating streptococcal infections

Assignees: New Horizons Diagnostics Corp; Rockefeller University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,014,850
App. No.
10/067,991
Granted
Mar 21, 2006
Kind
B2
Abstract

A nasal spray for treating a streptococcal infection is disclosed. The spray comprises an effective amount of a lysin enzyme genetically coded for by a C 1 bacteriophage capable of infecting a group C Streptococcal bacteria, and a nasal spray carrier for delivering said lysin enzyme to a mouth, throat, or nasal passage.

Claims (15)

1. A nasal spray for treating a streptococcal infection, comprising:

(i) an effective amount of a lysin enzyme genetically coded for by a C1 bacteriophage capable of infecting a group C Streptococcus bacteria, said lysin enzyme characterized by the ability to specifically destroy the cell wall of a Group A Streptococcili;

ii) a nasal spray for delivering said lysing enzyme to a or nasal passage; and

iii) a nasal sprayer for delivering said nasal spray.

2. The nasal spray according to claim 1 , further comprising a buffer that maintains pH of the nasal spray at a range between about 4.0 and 9.0.

3. The nasal spray according to claim 2 , wherein said buffer maintains the pH of the nasal spray at range between 5.5 and 7.5.

4. The nasal spray according to claim 2 , wherein said buffer comprises a reducing agent.

5. The nasal spray according to claim 4 , wherein said reducing agent is dithiothreitol.

6. The nasal spray according to claim 2 , wherein said buffer comprises a metal chelating agent.

7. The nasal spray according to 6 , wherein said metal chelating agent is ethyldiaminetetraacetic disodium salt.

8. The nasal spray according to claim 2 , wherein said buffer is a citrate-phosphate buffer.

9. The nasal spray according to claim 1 , wherein further comprising a bactericidal or bacteriostatic agent as a preservative.

10. The nasal spray according to claim 1 , wherein said lysin enzyme is lyophilized.

11. The nasal spray according to claim 1 , wherein said carrier further comprises a sweetener.

12. The nasal spray according to claim 1 , wherein said carrier is suitable for delivering said lysin enzyme to the nasal passage.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2003
From: FISCHETTI, VINCENT A.; NEW HORIZONS DIAGNOSTICS CORPORATION
To: ROCKEFELLER UNIVERSITY, THE
Reel/Frame 014043/0389 →
Continuity (5)
Continuation 0967188000 · Sep 28, 2000
Continuation In Part 0949749500 · Apr 18, 2000
Continuation 0939563600 · Sep 14, 1999
Continuation In Part 0896252300 · Oct 31, 1997
Related Publication 20020094330A1 · Jul 18, 2002